ArticleCureus2025
Renal Cell Carcinoma in Pregnancy With Breast Metastasis: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Usual: Breast, Pituitary and Gastric Metastases from Clear Cell Renal Cell Carcinomas-A Case Series with Review of Literature.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) during pregnancy is exceedingly rare and presents significant diagnostic and therapeutic challenges. We report the case of a 45-year-old gravida 3 woman in whom a right renal mass was incidentally identified during the second trimester. At 34 weeks of gestation, she underwent cesarean delivery followed by right radical nephrectomy. Histopathology revealed a 12 cm clear cell RCC with renal sinus invasion. Postpartum staging demonstrated multiple pulmonary metastases, and systemic therapy was initiated with cabozantinib plus nivolumab. Despite temporary stabilization, disease progression occurred, and subsequent lines of therapy included axitinib, everolimus, and sunitinib. During follow-up, a newly developed breast mass was confirmed as metastatic RCC, representing an exceptionally rare metastatic site. Comprehensive molecular profiling revealed pathogenic variants in NF1 and FBXW7, alterations that are associated with aggressive tumor biology and resistance to systemic therapy. Despite multidisciplinary management, the patient experienced rapid disease progression and died 13 months after diagnosis. This case underscores several important clinical considerations: the difficulty of establishing a timely diagnosis of RCC in pregnancy due to overlapping maternal symptoms, the need to balance maternal and fetal safety when planning surgical intervention, and the limitations of systemic therapy in the peripartum period. Furthermore, the presence of aggressive molecular alterations may contribute to resistance and poor outcomes. The rare occurrence of breast metastasis highlights the potential for unusual dissemination patterns in RCC. Reporting such uncommon cases contributes to improved understanding of disease behavior, helps guide clinical decision-making, and emphasizes the importance of individualized, multidisciplinary management in this challenging setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.